Prostatic Artery Embolization Offers Lasting Benefit for BPH
By Elana Gotkine HealthDay Reporter
THURSDAY, Oct. 3, 2024 -- For men with benign prostatic hyperplasia (BPH), prostatic artery embolization (PAE) is safe and effective over 24 months of follow-up, according to a study published online Sept. 4 in Cardiovascular and Interventional Radiology.
Marc R. Sapoval, M.D., Ph.D., from the Assistance Publique-Hôpitaux de Paris, and colleagues conducted an international trial of men with BPH with lower urinary tract symptoms (LUTS) or acute urinary retention (AUR) treated with PAE. Clinical outcomes were described over 24 months, with the primary outcome of 12-month change in the International Prostate Symptom Score (IPSS) or urinary catheter independence for patients referred for bothersome LUTS and treated for AUR, respectively.
The analyses included 478 patients who underwent PAE (405 with bothersome LUTS and 73 with AUR). The researchers found that the mean total IPSS at baseline was 21.8 for patients treated for bothersome LUTS, which significantly decreased to 9.3, 10.6, and 11.2 at three, 12, and 24 months after PAE, respectively. At baseline, quality of life (QoL) was 4.7 and decreased to 2.0, 2.1, and 2.3 at three, 12, and 24 months, respectively. The mean Sexual Health Inventory for Men score was 13.8 and 13.9 at baseline and 12 months following PAE, respectively. Overall, 65.8 percent of the patients treated for AUR had their indwelling catheter removed within three months of PAE and remained catheter-free at 24 months. Overall, 11.5 percent experienced one or more adverse events, and 2.1 percent experienced a serious adverse event.
"The mean changes in IPSS and QoL scores suggest durability of the clinical benefits associated with PAE," the authors write.
Several authors disclosed ties to pharmaceutical and medical device companies, including Merit Medical Systems, which funded the study.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted October 2024
Read this next
Random Forest AI Model Superior for Inpatient Mortality Prognostication in Cirrhosis
THURSDAY, July 24, 2025 -- For inpatients with cirrhosis, a machine learning (ML) model using random forest (RF) analysis is superior for prediction of inpatient mortality...
Inflammation and Nutrition-Based Scores Tied to Prognosis of Low-Risk Myelodysplastic Syndrome
THURSDAY, July 24, 2025 -- The Prognostic Nutritional Index (PNI) and systemic oxidative stress (SOS) score are independently associated with poorer prognosis of low-risk...
Few School Principals Report District-Mandated Mental Health Screening
THURSDAY, July 24, 2025 -- Few school principals report district-mandated mental health screening in schools, according to a study published online July 18 in JAMA Network...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.